Antagonistic therapeutic approaches to proinflammatory molecules such as IL-1β, IL-1 receptor (IL-1R), tumor necrosis factor (TNF), and C-C chemokine ligand (CCL)2 were shown to improve glycemic control and metabolic parameters in patients with type 2 diabetes (12). Here, TNF is linked to type 2 diabetes mellitus.